Insignificant disease among men with intermediate-risk prostate cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology
Link
http://link.springer.com/content/pdf/10.1007/s00345-014-1413-3.pdf
Reference19 articles.
1. Iremashvili V, Pelaez L, Manoharan M, Jorda M, Rosenberg DL, Soloway MS (2012) Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. Eur Urol 62:462–468
2. Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schröder FH, Roobol MJ (2012) Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 110:1672–1677
3. Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J (2013) Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial. Eur Urol 63:101–107
4. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR (2011) Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 29:228–234
5. Van der Kwast TH (2012) The trade-off between sensitivity and specificity of clinical protocols for identification of insignificant prostate cancer. Eur Urol 62:469–471
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Outcomes for active surveillance are similar for men with favourable risk ISUP-2 to those with ISUP-1 prostate cancer: A pair matched cohort study;Journal of Clinical Urology;2023-03-01
2. Active surveillance in intermediate-risk prostate cancer;BJU International;2020-01-16
3. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer;BMC Cancer;2019-05-06
4. A Tumor Suppressor-Regulated Cell Cycle Derived Gene Signature is Prognostic of Recurrence Risk in Prostate Cancer;2018-08-21
5. The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes;Prostate Cancer;2018-07-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3